Barbara Ryan is Director at MiNK Therapeutics, Inc. (INKT). They have made 7 open-market trades across 3 companies since 2022, most recently 2026-06-04.
CIK 0001827169
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $39K since 2022, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| INDV | 12,242 | $397K |
| INKT | 21,969 | $220K |
| INVO | 22,991 | $19K |
| Total | $636K |
Shares reported on the most recent Form 4, priced at the 2026-06-05 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INKT | SELL | 2026-06-04 | 2026-06-05 | $12.76 | $19K | +6.9% | +0.1% | -4.4% |
| INDV | BUY | 2026-03-13 | 2026-03-13 | $31.09 | $249 | -3.8% | +0.4% | +21.2% |
| INKT | SELL | 2026-03-09 | 2026-03-11 | $14.70 | $22K | -8.6% | +9.4% | +12.3% |
| INDV | BUY | 2026-03-09 | 2026-03-11 | $32.56 | $1K | -2.0% | +1.8% | +27.5% |
| INKT | SELL | 2026-02-27 | 2026-03-04 | $10.85 | $5K | -12.8% | +4.6% | +8.0% |
| INDV | BUY | 2026-01-05 | 2026-01-07 | $35.39 | $27K | -10.5% | -6.7% | -17.2% |
| INVO | BUY | 2022-06-01 | 2022-06-03 | $0.95 | $10K | -11.4% | -23.0% | -6.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.